Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition, Journal of Clinical Oncology, vol.24, issue.24, pp.3973-3981, 2006. ,
DOI : 10.1200/JCO.2005.04.0756
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes, Clinical Cancer Research, vol.15, issue.10, pp.3251-3256, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1171
Docetaxel and estramustine 28 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, vol.17, pp.3461-3468, 1999. ,
A new human prostate carcinoma cell line, 22Rv1, In Vitro Cellular & Developmental Biology - Animal, vol.54, issue.7, pp.403-412, 1999. ,
DOI : 10.1007/s11626-999-0115-4
Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice, Prog Clin Biol Res, vol.37, pp.67-84, 1980. ,
Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside, Neuroendocrine-like prostate cancer cells, pp.287-96, 2007. ,
DOI : 10.1159/000109711
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.280, issue.11, pp.969-74, 1998. ,
DOI : 10.1001/jama.280.11.969
Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer, The Journal of Urology, vol.181, issue.2, pp.601-608, 2009. ,
DOI : 10.1016/j.juro.2008.10.033
The role of beta-tubulin isotypes in resistance to antimitotic drugs, Biochim Biophys Acta, vol.1471, pp.1-9, 2001. ,
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells, Br J Cancer J Invest Dermatol, vol.80129, issue.37, pp.1020-51516, 1999. ,
??III-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability, Journal of Biological Chemistry, vol.280, issue.13, pp.12902-12909, 2005. ,
DOI : 10.1074/jbc.M414477200
Expression of Class III ??-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy, Clinical Cancer Research, vol.11, issue.15, pp.5481-5487, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0285
Expression of class III ?-tubulin reduces microtubule assembly and confers resistance to paclitaxel, Cell Motility and the Cytoskeleton, vol.10, issue.1, pp.45-56, 2003. ,
DOI : 10.1002/cm.10132
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients, Clin Cancer Res, vol.11, pp.298-305, 2005. ,
Class III ??-tubulin expression and in vitro resistance to microtubule targeting agents, British Journal of Cancer, vol.8, issue.2, pp.316-340 ,
DOI : 10.1016/S0169-5002(01)00291-4
Class III ??-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer, Cancer Research, vol.67, issue.19, pp.9356-63, 2007. ,
DOI : 10.1158/0008-5472.CAN-07-0509
Overexpression of class I, II or IVb ,
Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb ??-Tubulin in Vinca Alkaloid Sensitivity, Cancer Research, vol.68, issue.23, pp.9817-9841, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-1501
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer, Journal of Clinical Oncology, vol.25, issue.23, pp.3399-406, 2007. ,
DOI : 10.1200/JCO.2006.08.9102